Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence chatbots vs. YPUC pediatric urologists: performance on a Campbell Walsh urology hypospadiology questionnaire.

World journal of urology·2025
Same author

Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1.

Science signaling·2025
Same author

CAR T Cell Therapy's Potential for Pediatric Brain Tumors.

Cancers·2021
Same author

SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells.

Cancer immunology, immunotherapy : CII·2021
Same author

Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.

International journal of cancer·2019
Same author

Targeting <i>O</i>-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.

Journal of immunology research·2017

Related Experiment Video

Updated: May 20, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives.

Hortense Alliot1,2, Pierre Machy1, Marc-David Leclair2

  • 1Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F, Nantes, 44000, France.

Current Oncology Reports
|May 19, 2026
PubMed
Summary

Chimeric antigen receptor (CAR) T cell therapy targeting GD2 shows promise for high-risk neuroblastoma, demonstrating durable remissions and an acceptable safety profile in early trials. Further innovation may enhance outcomes for this challenging pediatric cancer.

Keywords:
CAR-T cellsGD2ImmunotherapyNeuroblastoma

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Related Experiment Videos

Last Updated: May 20, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Area of Science:

  • Pediatric Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • High-risk neuroblastoma presents a significant challenge in pediatric oncology.
  • Current multimodal therapies offer limited long-term survival rates.
  • GD2 is a validated target for neuroblastoma therapy.

Purpose of the Study:

  • To review recent advancements in GD2-directed chimeric antigen receptor (CAR) T cell therapy for neuroblastoma.
  • To assess the potential of CAR T cell therapy to improve outcomes in pediatric neuroblastoma.

Main Methods:

  • Systematic review of early-phase clinical trials involving GD2-directed CAR T cell therapy.
  • Analysis of objective response rates, duration of response, and safety profiles.
  • Evaluation of CAR T cell expansion, trafficking, and clinical activity in solid tumors.

Main Results:

  • Early trials reported objective responses from 6% to 33% and durable complete remissions exceeding 10 years.
  • Cytokine release syndrome and neurotoxicity were generally mild and rare.
  • CAR T cell therapy demonstrated measurable clinical activity, especially in minimal residual disease settings, with an acceptable safety profile.

Conclusions:

  • GD2-directed CAR T cell therapy shows potential for treating high-risk neuroblastoma.
  • Continued innovation in CAR design and multimodal integration is crucial for improving long-term outcomes.
  • This therapy offers a promising avenue for patients with relapsed or refractory neuroblastoma.